ID   MES-SA
AC   CVCL_1404
SY   MESSA
DR   CLO; CLO_0007677
DR   EFO; EFO_0002233
DR   CLDB; cl3447
DR   CLDB; cl3448
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1976
DR   BCRC; 60333
DR   BioSample; SAMN03470984
DR   BioSample; SAMN10987906
DR   cancercelllines; CVCL_1404
DR   Cell_Model_Passport; SIDM00625
DR   ChEMBL-Cells; CHEMBL3307599
DR   ChEMBL-Targets; CHEMBL614343
DR   Cosmic; 687553
DR   Cosmic; 848889
DR   Cosmic; 908127
DR   Cosmic; 2008739
DR   Cosmic-CLP; 908127
DR   DepMap; ACH-000449
DR   ECACC; 95051030
DR   EGA; EGAS00001000978
DR   GDSC; 908127
DR   GEO; GSM827389
DR   GEO; GSM1670096
DR   GEO; GSM1676304
DR   GEO; GSM1701639
DR   IARC_TP53; 21494
DR   ICLC; HTL96008
DR   IGRhCellID; MESSA
DR   LiGeA; CCLE_298
DR   LINCS_LDP; LCL-1509
DR   PharmacoDB; MESSA_916_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1404
DR   PubChem_Cell_line; CVCL_1404
DR   Wikidata; Q54905248
RX   PubMed=6883344;
RX   PubMed=15816562;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22889595;
RX   PubMed=25877200;
RX   PubMed=26351324;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-490.html
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 22-24 hours (ATCC=CRL-1976; ECACC=95051030).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (ATCC).
CC   Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Gly1610Trpfs*38 (c.4826dupC) (p.S1609fs) (c.4825_4826insC); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Thr1690Asnfs*8 (c.5068dupA) (c.5067_5068insA); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His272Thrfs*4 (c.813delT) (p.Phe271fs) (c.811delT); ClinVar=VCV000428208; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.13%; Native American=0%; East Asian, North=1.61%; East Asian, South=0.25%; South Asian=2.44%; European, North=50.63%; European, South=43.94% (PubMed=30894373).
CC   Derived from site: In situ; Uterus; UBERON=UBERON_0000995.
ST   Source(s): ATCC; Cosmic-CLP; ECACC; Genomics_Center_BCF_Technion; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D10S1248: 14,15
ST   D12S391: 17,25
ST   D13S317: 11,13
ST   D16S539: 11,12
ST   D18S51: 12,15
ST   D19S433: 14.2,15
ST   D1S1656: 14,17.3
ST   D21S11: 29,30.2
ST   D22S1045: 16
ST   D2S1338: 17
ST   D2S441: 10,14
ST   D3S1358: 14,17
ST   D5S818: 13
ST   D7S820: 7,11
ST   D8S1179: 14,15
ST   FGA: 20,25
ST   Penta D: 13,15
ST   Penta E: 7,10
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C6339; Uterine corpus sarcoma
DI   ORDO; Orphanet_213620; Sarcoma of the corpus uteri
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 37
//
RX   PubMed=6883344;
RA   Harker W.G., MacKintosh F.R., Sikic B.I.;
RT   "Development and characterization of a human sarcoma cell line, MES-SA,
RT   sensitive to multiple drugs.";
RL   Cancer Res. 43:4943-4950(1983).
//
RX   PubMed=15816562;
RA   Wesolowska O., Paprocka M., Kozlak J., Motohashi N., Dus D.,
RA   Michalak K.;
RT   "Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for
RT   multidrug resistance modulators screening.";
RL   Anticancer Res. 25:383-389(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22889595; DOI=10.1016/j.jprot.2012.07.047;
RA   Lin S.-T., Chou H.-C., Chang S.-J., Chen Y.-W., Lyu P.-C., Wang W.-C.,
RA   Chang M.D.-T., Chan H.-L.;
RT   "Proteomic analysis of proteins responsible for the development of
RT   doxorubicin resistance in human uterine cancer cells.";
RL   J. Proteomics 75:5822-5847(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//